Ciliatech SAS received a U.S. FDA investigational device exemption (IDE) to run a feasibility study of Intercil Uveal Spacer, its implant aimed at treating glaucoma. The step allows the company to initiate U.S. clinical evaluation of the device before broader commercialization. Intercil is intended to reduce treatment burden and improve intraocular outcomes by local delivery via an implanted spacer, shifting from traditional reliance on chronic drop-based regimens. The IDE milestone indicates the FDA’s acceptance of the company’s investigational plan for early human testing. The approval is a notable U.S. regulatory step for a med-tech entrant in a field dominated by pharmaceuticals and laser interventions, where durable positioning and safety signals are critical for payer and clinical adoption. For glaucoma, device-led approaches remain a high-stakes niche where feasibility trial design often determines next-stage outcomes.